ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

Peers & Perspectives in Oncology: Could you explain the recent indirect analysis of lurbinectedin (Zepzelca) vs topotecan in pretreated patients with ES-SCLC who have a chemotherapy-free interval ...

Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on ...

Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

Patients were stratified by the type of prior investigator’s choice chemotherapy they had received (paclitaxel vs pegylated liposomal doxorubicin [PLD] vs topotecan) and number of prior lines of ...

Patients with pretreated extensive small cell lung cancer could benefit from the antibody-drug conjugate ifinatamab ...

Present anti-cancer drugs — camptothecin, topotecan, and irinotecan — target a molecule (the enzyme topoisomerase 1 or Top1) involved in DNA metabolic processes like replication and transcription.